Value through Innovation27 July 2016

Clinical Study Results

  • VARGATEF ® - Mesothelioma
    Clinical Study Number 1199.93
    Study Indication Mesothelioma
    Product VARGATEF ®
    Generic Name Nintedanib
    Lab Code
    Clinical Phase II/III
    Study Title

    LUME-Meso: Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed/cisplatin followed by continuing nintedanib monotherapy vs. placebo in combination with pemetrexed/cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma

    Study Document Trial synopsis 1199.93_Overall_survival_PhaseII english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.